Assessing Teva Pharmaceutical Industries (TEVA) Valuation After New Biosimilar Approvals And Pipeline Progress

What Teva’s latest biosimilar milestones mean for investors

Teva Pharmaceutical Industries (NYSE:TEVA) has just reported three key milestones in its biosimilar portfolio, including US Food and Drug Administration approval for PONLIMSI as a biosimilar to Prolia and regulatory progress on a proposed Xolair biosimilar.

These product updates sit alongside a mixed share price backdrop, with the stock showing a 0.4% return over the past day and 2.7% over the past week, as well as declines over the month and past 3 months. This gives investors fresh information to weigh against recent volatility.

See our latest analysis for Teva Pharmaceutical Industries.

Teva’s recent biosimilar approvals and filings come after a period where short term momentum has cooled, with a 30 day share price return of 10.42% and year to date share price return of 2.26%. At the same time, the 1 year total shareholder return of 97.84% and 3 year total shareholder return of about 3.3x still point to a very strong longer term outcome that investors are reassessing against new growth and risk signals.

If this kind of product news has you thinking about where else growth stories could emerge in healthcare, it could be worth scanning 33 healthcare AI stocks

With Teva posting a 1 year total shareholder return of 97.84% yet still trading at what some models flag as an intrinsic discount of about 49%, investors now face a key question: is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 20.0% Undervalued

With Teva closing at $30.25 against a narrative fair value of $37.82, the current price sits meaningfully below what the most followed model suggests.

The accelerating launch cadence of biosimilars (with 8 launches targeted through 2027 and a goal to double biosimilar revenue), backed by favorable regulatory trends increasing biosimilar adoption in major markets, should unlock incremental, higher-margin revenue streams and offset headwinds from traditional generics, supporting long-term EBITDA growth.

Read the complete narrative.

Curious what earnings path and margin shift are built into that view? The narrative leans on steady top line assumptions and a richer profit mix to justify its fair value.

Result: Fair Value of $37.82 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, those projections could be challenged if reliance on a few branded drugs collides with pricing pressure, or if heavy debt limits how far Teva can push R&D and new launches.

Find out about the key risks to this Teva Pharmaceutical Industries narrative.

Another View: Earnings Multiple Sends A Different Signal

While the popular narrative flags Teva as 20.0% undervalued relative to a $37.82 fair value, the current P/E of 25x tells a different story. It sits above the estimated fair ratio of 21.6x, the US Pharmaceuticals average of 16.8x, and the 21.1x peer average. This points to valuation risk if expectations cool. Which signal do you give more weight to?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation and sentiment running both hopeful and cautious, it makes sense to move quickly and test the story against the numbers yourself by reviewing the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with just one company, you might miss other opportunities that better match your goals, risk comfort, and income needs across different parts of the market.

• Spot potential value opportunities early by scanning 63 high quality undervalued stocks that combine quality fundamentals with prices some investors may see as attractive.
• Strengthen the defensive side of your portfolio by reviewing the solid balance sheet and fundamentals stocks screener (39 results) and focusing on companies with sturdier finances.
• Unearth less followed opportunities by checking out the screener containing 25 high quality undiscovered gems that many investors might not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com